Scott Robertson
Director/Board Member presso Bicara Therapeutics, Inc.
Profilo
Scott Robertson is currently the Director at Bicara Therapeutics, Inc. and a Venture Partner at Finistere Ventures LLC.
He previously worked as the Director of Business Development at EIDP, Inc., an Associate at MPM BioEquities Adviser LLC and MPM BioImpact, Inc., and as the Chief Financial Officer at DICE Molecules SV, Inc. He also served as an Independent Non-Executive Director at Hexima Ltd.
from 2018 to 2023.
Robertson received his undergraduate degree from the University of Southern California and his MBA from the Haas School of Business.
Posizioni attive di Scott Robertson
Società | Posizione | Inizio |
---|---|---|
Finistere Ventures LLC
Finistere Ventures LLC Investment ManagersFinance Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California. | Private Equity Investor | 01/01/2016 |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16/10/2023 |
Precedenti posizioni note di Scott Robertson
Società | Posizione | Fine |
---|---|---|
HEXIMA LIMITED | Director/Board Member | 05/09/2023 |
E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | - |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Analyst | - |
MPM BioEquities Adviser LLC
MPM BioEquities Adviser LLC Investment ManagersFinance Founded in 1997 by Ansbert Gadicke and Luke Evnin, MPM BioEquities Adviser LLC is a hedge fund manager located in South San Francisco, California with an additional office in Boston. The firm is a subsidiary of MPM Capital LP, a private equity firm. | Analyst-Equity | - |
Formazione di Scott Robertson
University of Southern California | Undergraduate Degree |
Haas School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
HEXIMA LIMITED | Health Technology |
Aziende private | 6 |
---|---|
EIDP, Inc.
EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
MPM BioEquities Adviser LLC
MPM BioEquities Adviser LLC Investment ManagersFinance Founded in 1997 by Ansbert Gadicke and Luke Evnin, MPM BioEquities Adviser LLC is a hedge fund manager located in South San Francisco, California with an additional office in Boston. The firm is a subsidiary of MPM Capital LP, a private equity firm. | Finance |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Finistere Ventures LLC
Finistere Ventures LLC Investment ManagersFinance Finistere Ventures LLC (Finistere Ventures) is a venture capital firm founded by Spencer Maughan and Arama Kukutai in 2005. The firm is headquartered in Newport Beach, California. | Finance |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Finance |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
- Borsa valori
- Insiders
- Scott Robertson